Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection (Q44700462)

5 December 2017

title

Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection (English)

1 reference

5 December 2017

main subject

decompensated cirrhosis

1 reference

1 reference

Spilios Manolakopoulos

1 reference

5 December 2017

Stylianos Karatapanis

1 reference

5 December 2017

Jiannis Elefsiniotis

1 reference

5 December 2017

Nicoletta Mathou

1 reference

5 December 2017

Jiannis Vlachogiannakos

1 reference

5 December 2017

Elissabet Iliadou

1 reference

5 December 2017

Anastasios Kougioumtzan

1 reference

5 December 2017

Michalis Economou

1 reference

5 December 2017

Christos Triantos

1 reference

5 December 2017

Dimitrios Tzourmakliotis

1 reference

5 December 2017

Alec Avgerinos

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

The American Journal of Gastroenterology

5 December 2017

published in

1 reference

5 December 2017

1 reference

5 December 2017

1 reference

5 December 2017

page(s)

57-63

1 reference

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Diagnosis and management of pre-core mutant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1572-0241.2003.04021.X

10.1046/J.1572-0241.2003.04021.X

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference